title: Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
abstract: We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2alpha-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2alpha-isoprostanes after 3 or 6 months of treatment.
authors.affiliation: Department of Pediatrics, Obstetrics and Gynaecology, University of Valencia, Valencia, Spain.
authors.forename: Pilar J
authors.initials: PJ
authors.lastname: Oviedo
authors.forename: Carlos
authors.initials: C
authors.lastname: Hermenegildo
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Tarín
authors.forename: Antonio
authors.initials: A
authors.lastname: Cano
mesh_terms: D000975:Antioxidants / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000517:prevention & control*; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D009195:Peroxidase / Q000097:blood*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D028441:F2-Isoprostanes; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D009195:Peroxidase